Summary of results from primary and secondary outcomes assessment (intention-to-treat population)
| HA (n=149) | Placebo (n=152) | p Value | |
|---|---|---|---|
| Primary outcome | |||
| Responders OARSI 2004 at end of follow-up, n (%) | 120 (80.5) | 100 (65.8) | 0.004 |
| Secondary outcomes | |||
| Responders OARSI 2004 at each cycle assessments, n (%) | |||
| 7 months | 106 (71.1) | 103 (67.8) | 0.525 |
| 14 months | 114 (76.5) | 99 (65.1) | 0.030 |
| 21 months | 116 (77.9) | 103 (67.8) | 0.049 |
| 27 months | 116 (77.9) | 103 (67.8) | 0.049 |
| 34 months | 121 (81.2) | 99 (65.1) | 0.002 |
| Pain or function reduction 50% (20 mm), n (%) | 97 (65.1) | 79 (52.0) | 0.021 |
| Overall pain reduction 20% (10 mm), n (%) | 118 (79.2) | 103 (67.8) | 0.025 |
| Function improvement 20% (10 mm), n (%) | 105 (70.5) | 88 (57.9) | 0.023 |
| Patient's global assessment reduction 20% (10 mm), n (%) | 111 (74.5) | 88 (57.9) | 0.002 |
| Mean consumption of paracetamol, mg/day (SD) | 408.8 (644.2) | 451.4 (925.8) | NS |
HA, hyaluronic acid; OARSI, Osteoarthritis Research Society International.